Sepsis death rates ‘double’ previous figures
The new study included data from low- and middle-income countries, bringing the estimated total from 5.3 million deaths to 11 million.
Read More
Tag: death
Death risk from sepsis lasts up to five years
The research, published in JAMA Network Open today, found that 15% of sepsis survivors died within a year of leaving hospital.
Read More
Prostate cancer mutation found to triple risk of death
The research also identified clues for how some patients with prostate cancer could be treated more effectively using immunotherapy and a breast cancer treatment.
Read More
FDA pushes for stronger warnings on insomnia medicines
The change comes after reports of rare but serious injuries and deaths resulting from various complex sleep behaviours.
Read More
Affimed shares plunge on trial death
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death.
Read More
SGLT-2 inhibitors cut risk of death in diabetics, data shows
AstraZeneca has unveiled findings of a new analysis of data from the CVD-REAL study, showing a significant cut in the risk of all-cause death (ACD) in patients with type II diabetes taking SGLT-2 inhibitors.
Read More
FDA holds trials of Cellectis’ cell therapy after patient death
US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
Read More
Dementia now leading cause of death in England and Wales
Alzheimer’s disease and other dementias are now the leading cause of death in England and Wales, knocking heart disease off of the top spot for the first time, according to new figures from the Office of National Statistics (ONS).
Read More
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
